Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) Revenue
Annual & quarterly revenue history · segment & region breakdown
NTLA · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsIntellia Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.07B, an increase of 16.92% year-over-year from $0.07B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.07B | +$0.01B | +16.92% |
| 2024-12-31 | $0.06B | +$0.02B | +59.55% |
| 2023-12-31 | $0.04B | -$0.02B | -30.40% |
| 2022-12-31 | $0.05B | +$0.02B | +57.69% |
| 2021-12-31 | $0.03B | -$0.02B | -43.01% |
| 2020-12-31 | $0.06B | +$0.01B | +34.55% |
| 2019-12-31 | $0.04B | +$0.01B | +41.63% |
| 2018-12-31 | $0.03B | +$0.00B | +16.53% |
| 2017-12-31 | $0.03B | +$0.01B | +58.49% |
| 2016-12-31 | $0.02B | +$0.01B | +172.65% |
Compare revenue vs peers
BiotechnologyCompare NTLA revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Intellia Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Intellia Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Intellia Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NTLA revenue · 4 questionsNTLA's trailing twelve-month (TTM) revenue is $0.07B. That is an increase of 16.92% year-over-year from $0.07B in FY2025.
▸ Source: FMP · Intellia Therapeutics, Inc. SEC filings · GAAP · Intellia Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026